Cosmo and Glenmark receives market authorization of Winlevi in Europe
Winlevi is authorized in EU for the treatment of acne vulgaris
Winlevi is authorized in EU for the treatment of acne vulgaris
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Combination shows consistent benefit across prespecified post-progression outcomes
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Subscribe To Our Newsletter & Stay Updated